id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-1145-0041,FDA,FDA-2012-D-1145,Enrichment Strategies for Clinical Trials to Support Determination of Effectiveness of Human Drugs and Biological Products; Guidance for Industry,Other,Guidance,2019-03-15T04:00:00Z,2019,3,2019-03-15T04:00:00Z,,2024-11-12T22:57:27Z,,1,0,0900006483ae8344
FDA-2012-D-1145-0040,FDA,FDA-2012-D-1145,"Enrichment Strategies for Clinical Trials To Support Demonstration of
Effectiveness of Human Drugs and Biological Products; Guidance for
Industry; Availability",Notice,Notice of Availability,2019-03-15T04:00:00Z,2019,3,2019-03-15T04:00:00Z,,2019-03-15T13:51:58Z,2019-04815,0,0,0900006483ae7baf
FDA-2012-D-1145-0005,FDA,FDA-2012-D-1145,Draft Guidance for Industry on Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products; Extension of Comment Period,Notice,Extension of Comment Period,2013-02-04T05:00:00Z,2013,2,2013-02-04T05:00:00Z,2013-03-19T03:59:59Z,2013-03-19T02:02:30Z,2013-02293,0,0,09000064811e4dd1
FDA-2012-D-1145-0001,FDA,FDA-2012-D-1145,Draft Guidances for Industry on Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products; Availability,Notice,Notice of Availability,2012-12-17T05:00:00Z,2012,12,2012-12-17T05:00:00Z,2013-02-16T04:59:59Z,2013-02-15T03:02:38Z,2012-30274,0,0,090000648118f64f
FDA-2012-D-1145-0002,FDA,FDA-2012-D-1145,Draft Guidances for Industry on Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products,Other,Guidance,2012-12-17T05:00:00Z,2012,12,2012-12-17T05:00:00Z,,2024-11-12T05:11:04Z,,1,0,090000648118f80c